Eli Lilly (LLY) EBT (QoQ) (2009 - 2026)
Eli Lilly (LLY) EBT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.06% |
| Dec 31, 2025 | 14.29% |
| Sep 30, 2025 | 6.73% |
| Jun 30, 2025 | 96.08% |
| Mar 31, 2025 | -31.41% |
| Dec 31, 2024 | 217.19% |
| Sep 30, 2024 | -54.84% |
| Jun 30, 2024 | 38.69% |
| Mar 31, 2024 | 1.11% |
| Dec 31, 2023 | 487.13% |
| Sep 30, 2023 | -79.55% |
| Jun 30, 2023 | 36.56% |
| Mar 31, 2023 | -27.03% |
| Dec 31, 2022 | 33.91% |
| Sep 30, 2022 | 43.51% |
| Jun 30, 2022 | -46.88% |
| Mar 31, 2022 | 11.61% |
| Dec 31, 2021 | 47.75% |
| Sep 30, 2021 | -21.87% |
| Jun 30, 2021 | 7.96% |